AEGiS-14IAC: Reduction of HBV DNA plasma levels after addition of tenofovir in HBV/HIV-infected patients failing or partially responding to lamivudine.

14th International AIDS Conference

Barcelona, Spain - July 7-12, 2002

Reduction of HBV DNA plasma levels after addition of tenofovir in HBV/HIV-infected patients failing or partially responding to lamivudine.

Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeB9015)

Nunez M, Perez-Olmeda M, Diaz B, Rios P, Garcia-Samaniego J, Gonzalez-Lahoz J, Soriano V
H. Carlos III, Madrid, Spain

BACKGROUND: Treatment of hepatitis B virus (HBV) infection with lamivudine (3TC) may not completely suppress viral replication and often fails over time due to the development of 3TC resistance. Tenofovir Dixoproxil Fumarate (TDF) is a nucleotide analogue reverse transcriptase inhibitor active against HIV and both wild-type and 3TC-resistant HBV. The anti-HBV activity of TDF was explored in HBV/HIV-coinfected patients already under a 3TC-containing antiretroviral regimen.

METHODS: All HBV/HIV-coinfected patients with detectable HBV-DNA at the time of addition of TDF to their 3TC-containing regimens were selected at our institution. 3TC-resistance HBV mutations were examined at baseline. Follow-up HBV-DNA levels were measured every 12 weeks.

RESULTS: One female and 8 males with a median age of 40 years-old were studied. They had received 3TC for a median of 84 weeks. 6/9 were HBeAg positive, and 3/12 were also infected with hepatitis C virus. The median baseline HBV-DNA levels was 4,970,000 copies/ml. 3TC-resistance mutations at positions 552 plus/minus 528 were found in 6 subjects. In the remaining 3, good adherence to the medication was ascertained. The median time to follow-up was 24 weeks (range, 12-48). No side effects related to TDF were reported. All patients had a significant decrease in HBV DNA levels, with a median (range) drop of 2.89 (0.71-4.70) log₁₀ at 12-24 weeks. One patient lost the HBsAg at 48 weeks, and has remained with undetectable HBV-DNA thereafter.

CONCLUSIONS: TDF is very effective at reducing HBV DNA levels in HIV/HBV coinfected patients carrying either wild type or 3TC-resistant viruses.

Keywords: AEGIS, Lamivudine, Adenine, HIV, Organophosphorus Compounds, HIV Infections, Reverse Transcriptase Inhibitors, Hepatitis B Virus, Anti-HIV Agents, Hepatitis B e Antigens, Virus Replication, HIV Seropositivity, DNA, DNA, Viral, tenofovir, Human, Male, Female, immunology, virology

020707
LbPeB9015